As one of three core laboratories in the RCMI program, the Cell, Molecular and Bioinformatics Core (CMB Core) will continue to provide state of the art comprehensive cell and molecular biology as well as in vitro bioassay support to a wide range of biomedical research projects at Xavier University. The core will further expand its capabilities to include Next-Generation sequencing, antibody Arrays and cell based pharmacokinetics assays. With a newly-added bioinformatics facility, the core will also be able to provide comprehensive statistical, genomic and pathway analysis services. The long term goal of the CMB Core is to improve the biomedical research capacity of Xavier University by enhancing the capabilities of biomedical research projects and programs on campus. To achieve this goal, the CMB Core has three specific aims: 1) Provide cell, molecular and bioinformatics support services to faculty research projects. 2) Provide direct support to the RCMI Major Instrument and Drug Discovery and Delivery Cores. 3) Provide technical training and education to researchers at Xavier and local institutions. The CMB Core will be managed by a faculty director responsible for cell and molecular activities and a co-director responsible for bioinformatics facility services. The core will provide salary support for three staff scientists (two PhDs) that are complemented by two core staff (one PhD) supported by the Louisiana Cancer Research Consortium. Together, these core staff will provide a wide range of expertise to cover all core services. Operation of the core is specified in the Core Operation Plan (COP) that will be continually updated by the Core Advisory Committee (CAC).

Agency
National Institute of Health (NIH)
Institute
National Institute on Minority Health and Health Disparities (NIMHD)
Type
Research Centers in Minority Institutions Award (G12)
Project #
5G12MD007595-10
Application #
9460928
Study Section
Special Emphasis Panel (ZMD1)
Project Start
Project End
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
10
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Xavier University of Louisiana
Department
Type
DUNS #
020857876
City
New Orleans
State
LA
Country
United States
Zip Code
70125
Komati, Rajesh; Mitchell, Carl A; LeBeaud, Anastasia et al. (2018) Tenacic Acids: A New Class of Tenacious Binders to Metal Oxide Surfaces. Chemistry 24:14824-14829
Yao, Xin; Gray, Selena; Pham, Tri et al. (2018) Downregulation of Bit1 expression promotes growth, anoikis resistance, and transformation of immortalized human bronchial epithelial cells via Erk activation-dependent suppression of E-cadherin. Biochem Biophys Res Commun 495:1240-1248
Toro, Tasha B; Edenfield, Samantha A; Hylton, Brandon J et al. (2018) Chelatable trace zinc causes low, irreproducible KDAC8 activity. Anal Biochem 540-541:9-14
Echeverri, Margarita; Anderson, David; Nápoles, Anna María et al. (2018) Cancer Health Literacy and Willingness to Participate in Cancer Research and Donate Bio-Specimens. Int J Environ Res Public Health 15:
Schexnayder, Chandler; Broussard, Kiera; Onuaguluchi, Demitrius et al. (2018) Metformin Inhibits Migration and Invasion by Suppressing ROS Production and COX2 Expression in MDA-MB-231 Breast Cancer Cells. Int J Mol Sci 19:
Ponnapakkam, Tulasi; Saulsberry, Tyjah; Hill, Tarius et al. (2018) Inhibition of breast tumor growth in mice after treatment with ceramide analog 315. Anticancer Drugs 29:898-903
Al-Horani, Rami A; Afosah, Daniel K (2018) Recent advances in the discovery and development of factor XI/XIa inhibitors. Med Res Rev 38:1974-2023
Mei, Suyu; Flemington, Erik K; Zhang, Kun (2018) Transferring knowledge of bacterial protein interaction networks to predict pathogen targeted human genes and immune signaling pathways: a case study on M. tuberculosis. BMC Genomics 19:505
Aqeel, Salem M; Huang, Zhongyuan; Walton, Jonathan et al. (2018) Polyvinylidene Fluoride (PVDF)/Polyacrylonitrile (PAN)/Carbon Nanotube Nanocomposites for Energy Storage and Conversion. Adv Compos Hybrid Mater 1:185-192
Zheng, Shilong; Guo, Shanchun; Zhong, Qiu et al. (2018) Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors. ACS Med Chem Lett 9:149-154

Showing the most recent 10 out of 244 publications